CML

Key clinical point: Inotuzumab ozogamicin with bosutinib was well tolerated in patients with relapsed/refractory (R/R) lymphoid blast phase of chronic myeloid leukemia (CML-LBP) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Major finding: Rates of complete response (CR)/CR with incomplete count recovery, complete cytogenic response, measurable residual disease negativity, and complete molecular response were 83%, 81%, 61%, and 56%, respectively. The 30-day mortality was 0%. During the median follow-up of 44 months, median event-free survival and overall survival were 7.7 and 13.5 months, respectively. No patients discontinued treatment because of toxicity, and no veno-occlusive disease was reported.

Study details: This was a phase 1/2 trial including 18 patients with R/R Ph+ALL (n=16) or CML-LBP (n=2). The maximum tolerated dose of bosutinib was 400 mg daily.

Disclosures: This study was funded by Pfizer, MD Anderson Cancer Center Support Grant, and the National Cancer Institute. Some investigators including the lead author reported ties with various pharmaceutical companies, including Pfizer.

Source: Jain N et al. Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.

Key clinical point: Inotuzumab ozogamicin with bosutinib was well tolerated in patients with relapsed/refractory (R/R) lymphoid blast phase of chronic myeloid leukemia (CML-LBP) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Major finding: Rates of complete response (CR)/CR with incomplete count recovery, complete cytogenic response, measurable residual disease negativity, and complete molecular response were 83%, 81%, 61%, and 56%, respectively. The 30-day mortality was 0%. During the median follow-up of 44 months, median event-free survival and overall survival were 7.7 and 13.5 months, respectively. No patients discontinued treatment because of toxicity, and no veno-occlusive disease was reported.

Study details: This was a phase 1/2 trial including 18 patients with R/R Ph+ALL (n=16) or CML-LBP (n=2). The maximum tolerated dose of bosutinib was 400 mg daily.

Disclosures: This study was funded by Pfizer, MD Anderson Cancer Center Support Grant, and the National Cancer Institute. Some investigators including the lead author reported ties with various pharmaceutical companies, including Pfizer.

Source: Jain N et al. Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.

Key clinical point: Inotuzumab ozogamicin with bosutinib was well tolerated in patients with relapsed/refractory (R/R) lymphoid blast phase of chronic myeloid leukemia (CML-LBP) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Major finding: Rates of complete response (CR)/CR with incomplete count recovery, complete cytogenic response, measurable residual disease negativity, and complete molecular response were 83%, 81%, 61%, and 56%, respectively. The 30-day mortality was 0%. During the median follow-up of 44 months, median event-free survival and overall survival were 7.7 and 13.5 months, respectively. No patients discontinued treatment because of toxicity, and no veno-occlusive disease was reported.

Study details: This was a phase 1/2 trial including 18 patients with R/R Ph+ALL (n=16) or CML-LBP (n=2). The maximum tolerated dose of bosutinib was 400 mg daily.

Disclosures: This study was funded by Pfizer, MD Anderson Cancer Center Support Grant, and the National Cancer Institute. Some investigators including the lead author reported ties with various pharmaceutical companies, including Pfizer.

Source: Jain N et al. Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.

Key clinical point: Polymorphisms of CYP2A6 and ABCC4 genes were associated with a protective effect against the development of chronic myeloid leukemia (CML). These findings highlight the underlying genetic predisposition of individuals to develop CML.

Major finding: Individuals with the C allele of the rs28399433 polymorphism of CYP2A6 gene (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.14-0.78; P = .008) and the CC genotype of the rs3742106 polymorphism of ABCC4 gene (OR, 0.30; 95% CI, 0.10-0.88; P = .020) had a significantly reduced susceptibility to CML vs. other genotypes.

Study details: This retrospective study assessed an admixed population of 269 individuals including 143 patients with CML and 126 healthy controls from the Amazon region of Brazil.

Disclosures: No specific funding source was identified. The authors declared no conflicts of interest.

Source: Monte N et al. Mol Genet Genomic Med. 2021 May 29. doi: 10.1002/mgg3.1694.

Key clinical point: Polymorphisms of CYP2A6 and ABCC4 genes were associated with a protective effect against the development of chronic myeloid leukemia (CML). These findings highlight the underlying genetic predisposition of individuals to develop CML.

Major finding: Individuals with the C allele of the rs28399433 polymorphism of CYP2A6 gene (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.14-0.78; P = .008) and the CC genotype of the rs3742106 polymorphism of ABCC4 gene (OR, 0.30; 95% CI, 0.10-0.88; P = .020) had a significantly reduced susceptibility to CML vs. other genotypes.

Study details: This retrospective study assessed an admixed population of 269 individuals including 143 patients with CML and 126 healthy controls from the Amazon region of Brazil.

Disclosures: No specific funding source was identified. The authors declared no conflicts of interest.

Source: Monte N et al. Mol Genet Genomic Med. 2021 May 29. doi: 10.1002/mgg3.1694.

Key clinical point: Polymorphisms of CYP2A6 and ABCC4 genes were associated with a protective effect against the development of chronic myeloid leukemia (CML). These findings highlight the underlying genetic predisposition of individuals to develop CML.

Major finding: Individuals with the C allele of the rs28399433 polymorphism of CYP2A6 gene (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.14-0.78; P = .008) and the CC genotype of the rs3742106 polymorphism of ABCC4 gene (OR, 0.30; 95% CI, 0.10-0.88; P = .020) had a significantly reduced susceptibility to CML vs. other genotypes.

Study details: This retrospective study assessed an admixed population of 269 individuals including 143 patients with CML and 126 healthy controls from the Amazon region of Brazil.

Disclosures: No specific funding source was identified. The authors declared no conflicts of interest.

Source: Monte N et al. Mol Genet Genomic Med. 2021 May 29. doi: 10.1002/mgg3.1694.

Key clinical point: The Eutos long-term survival (ELTS) score appeared better at predicting overall survival (OS) in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), redefining the risk stratification obtained with the Sokal score. Patients defined as high risk by ELTS showed poorer OS, thereby warranting treatment intensification and close monitoring.

Major finding: A prognostic refinement was observed from the Sokal to the ELTS score in high and intermediate Sokal risk patients. In the high-risk Sokal group, 3-year OS ranged from 94.8% to 82.4% for patients considered at ‘true’ high risk. In the intermediate Sokal risk group, 3-year OS of high-risk patients was only 70.7% vs. 95.4% for low-risk and 87.9% for ‘true’ intermediate-risk patients.

Study details: Findings are from the analysis of 1,206 patients with CML from the GIMEMA observational study. Patients were treated with either imatinib (n=608) or second-generation TKIs, dasatinib, or nilotinib (n=598).

Disclosures: No source of funding was identified. Some investigators including the lead author reported honoraria from various pharmaceutical companies.

Source: Breccia M et al. Leukemia. 2021 May 17. doi: 10.1038/s41375-021-01292-4.

Key clinical point: The Eutos long-term survival (ELTS) score appeared better at predicting overall survival (OS) in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), redefining the risk stratification obtained with the Sokal score. Patients defined as high risk by ELTS showed poorer OS, thereby warranting treatment intensification and close monitoring.

Major finding: A prognostic refinement was observed from the Sokal to the ELTS score in high and intermediate Sokal risk patients. In the high-risk Sokal group, 3-year OS ranged from 94.8% to 82.4% for patients considered at ‘true’ high risk. In the intermediate Sokal risk group, 3-year OS of high-risk patients was only 70.7% vs. 95.4% for low-risk and 87.9% for ‘true’ intermediate-risk patients.

Study details: Findings are from the analysis of 1,206 patients with CML from the GIMEMA observational study. Patients were treated with either imatinib (n=608) or second-generation TKIs, dasatinib, or nilotinib (n=598).

Disclosures: No source of funding was identified. Some investigators including the lead author reported honoraria from various pharmaceutical companies.

Source: Breccia M et al. Leukemia. 2021 May 17. doi: 10.1038/s41375-021-01292-4.

Key clinical point: The Eutos long-term survival (ELTS) score appeared better at predicting overall survival (OS) in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), redefining the risk stratification obtained with the Sokal score. Patients defined as high risk by ELTS showed poorer OS, thereby warranting treatment intensification and close monitoring.

Major finding: A prognostic refinement was observed from the Sokal to the ELTS score in high and intermediate Sokal risk patients. In the high-risk Sokal group, 3-year OS ranged from 94.8% to 82.4% for patients considered at ‘true’ high risk. In the intermediate Sokal risk group, 3-year OS of high-risk patients was only 70.7% vs. 95.4% for low-risk and 87.9% for ‘true’ intermediate-risk patients.

Study details: Findings are from the analysis of 1,206 patients with CML from the GIMEMA observational study. Patients were treated with either imatinib (n=608) or second-generation TKIs, dasatinib, or nilotinib (n=598).

Disclosures: No source of funding was identified. Some investigators including the lead author reported honoraria from various pharmaceutical companies.

Source: Breccia M et al. Leukemia. 2021 May 17. doi: 10.1038/s41375-021-01292-4.

Key clinical point: In a large cohort of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) receiving frontline imatinib therapy, adolescents showed adverse disease features and shorter failure-free survival (FFS) compared with children, indicating distinct disease characteristics and outcomes between these pediatric groups.

Major finding: Adolescents vs. children presented with significantly higher white blood cell count (P = .033), basophil percentage in peripheral blood (P = .002), and prevalence of splenomegaly (P = .004). Children had a longer FFS vs. adolescents (hazard ratio, 2.36; P = .015).

Study details: Findings are from a retrospective analysis of 982 newly diagnosed patients with CML-CP, including 135 children, 189 adolescents, and 658 adults, who received imatinib as the first-line treatment within 6 months of diagnosis.

Disclosures: This study was funded by the National Natural Science Foundation of China. No author disclosures were reported.

Source: Dou X et al. Ann Hematol. 2021 Jun 5. doi: 10.1007/s00277-021-04544-6.

Key clinical point: In a large cohort of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) receiving frontline imatinib therapy, adolescents showed adverse disease features and shorter failure-free survival (FFS) compared with children, indicating distinct disease characteristics and outcomes between these pediatric groups.

Major finding: Adolescents vs. children presented with significantly higher white blood cell count (P = .033), basophil percentage in peripheral blood (P = .002), and prevalence of splenomegaly (P = .004). Children had a longer FFS vs. adolescents (hazard ratio, 2.36; P = .015).

Study details: Findings are from a retrospective analysis of 982 newly diagnosed patients with CML-CP, including 135 children, 189 adolescents, and 658 adults, who received imatinib as the first-line treatment within 6 months of diagnosis.

Disclosures: This study was funded by the National Natural Science Foundation of China. No author disclosures were reported.

Source: Dou X et al. Ann Hematol. 2021 Jun 5. doi: 10.1007/s00277-021-04544-6.

Key clinical point: In a large cohort of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) receiving frontline imatinib therapy, adolescents showed adverse disease features and shorter failure-free survival (FFS) compared with children, indicating distinct disease characteristics and outcomes between these pediatric groups.

Major finding: Adolescents vs. children presented with significantly higher white blood cell count (P = .033), basophil percentage in peripheral blood (P = .002), and prevalence of splenomegaly (P = .004). Children had a longer FFS vs. adolescents (hazard ratio, 2.36; P = .015).

Study details: Findings are from a retrospective analysis of 982 newly diagnosed patients with CML-CP, including 135 children, 189 adolescents, and 658 adults, who received imatinib as the first-line treatment within 6 months of diagnosis.

Disclosures: This study was funded by the National Natural Science Foundation of China. No author disclosures were reported.

Source: Dou X et al. Ann Hematol. 2021 Jun 5. doi: 10.1007/s00277-021-04544-6.

Key clinical point: Administration of a single dose of SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech) led to seroconversion and T-cell response in most patients with chronic-phase chronic myeloid leukemia (CML-CP), with neutralizing antibody responses in all.

Major finding: After 3 weeks of BNT162b2 administration, anti-Spike immunoglobulin G and neutralizing antibodies were observed in 87.5% and 100% of patients, respectively. A memory T-cell response was observed in 93.3% of patients, with a polyfunctional cytokine response in either CD4⁺ or CD8⁺ T cells in 80% of patients.

Study details: Findings are from an analysis of 16 adult patients with CML-CP who received the first injection of 30 mg BNT162b2.

Disclosures: This study was funded by King’s Together Rapid COVID-19 Call Award, Huo Family Foundation Award, Chronic Disease Research Foundation award, Wellcome Trust Investigator Award, MRC-KCL Doctoral Training Partnership in Biomedical Sciences, Fondation Dormeur (Vaduz), Blood Cancer UK, LifeArc, Cancer Research UK, and King’s Health Partners Centre.

Source: Harrington P et al. Br J Haematol. 2021 June 3. doi: 10.1111/bjh.17568.

Key clinical point: Administration of a single dose of SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech) led to seroconversion and T-cell response in most patients with chronic-phase chronic myeloid leukemia (CML-CP), with neutralizing antibody responses in all.

Major finding: After 3 weeks of BNT162b2 administration, anti-Spike immunoglobulin G and neutralizing antibodies were observed in 87.5% and 100% of patients, respectively. A memory T-cell response was observed in 93.3% of patients, with a polyfunctional cytokine response in either CD4⁺ or CD8⁺ T cells in 80% of patients.

Study details: Findings are from an analysis of 16 adult patients with CML-CP who received the first injection of 30 mg BNT162b2.

Disclosures: This study was funded by King’s Together Rapid COVID-19 Call Award, Huo Family Foundation Award, Chronic Disease Research Foundation award, Wellcome Trust Investigator Award, MRC-KCL Doctoral Training Partnership in Biomedical Sciences, Fondation Dormeur (Vaduz), Blood Cancer UK, LifeArc, Cancer Research UK, and King’s Health Partners Centre.

Source: Harrington P et al. Br J Haematol. 2021 June 3. doi: 10.1111/bjh.17568.

Key clinical point: Administration of a single dose of SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech) led to seroconversion and T-cell response in most patients with chronic-phase chronic myeloid leukemia (CML-CP), with neutralizing antibody responses in all.

Major finding: After 3 weeks of BNT162b2 administration, anti-Spike immunoglobulin G and neutralizing antibodies were observed in 87.5% and 100% of patients, respectively. A memory T-cell response was observed in 93.3% of patients, with a polyfunctional cytokine response in either CD4⁺ or CD8⁺ T cells in 80% of patients.

Study details: Findings are from an analysis of 16 adult patients with CML-CP who received the first injection of 30 mg BNT162b2.

Disclosures: This study was funded by King’s Together Rapid COVID-19 Call Award, Huo Family Foundation Award, Chronic Disease Research Foundation award, Wellcome Trust Investigator Award, MRC-KCL Doctoral Training Partnership in Biomedical Sciences, Fondation Dormeur (Vaduz), Blood Cancer UK, LifeArc, Cancer Research UK, and King’s Health Partners Centre.

Source: Harrington P et al. Br J Haematol. 2021 June 3. doi: 10.1111/bjh.17568.

Key clinical point: Protein tyrosine phosphatase receptor gamma (PTPRG), a tumor suppressor gene, could serve as a new biomarker to evaluate therapeutic response to tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML).

Major finding: In patients with CML, PTPRG expression was significantly lower at diagnosis vs. follow-up (P less than .001). Patients with optimal response to TKI had significantly higher PTPRG expression during follow-up vs. diagnosis (P less than .0005); however, no difference was observed in patients with a failed response to TKI (P = .312).

Study details: This study assessed PTPRG expression in 21 patients with CML (chronic phase, n=18; accelerated phase, n=3) treated with imatinib (n=12) or nilotinib (n=9) and 7 healthy individuals.

Disclosures: This study was funded by the Qatar National Research Fund, and open access funding was enabled by the Qatar National Library. The authors declared no conflicts of interest.

Source: Ismail MA et al. Sci Rep. 2021 Apr 23. doi: 10.1038/s41598-021-86875-y.

Key clinical point: Protein tyrosine phosphatase receptor gamma (PTPRG), a tumor suppressor gene, could serve as a new biomarker to evaluate therapeutic response to tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML).

Major finding: In patients with CML, PTPRG expression was significantly lower at diagnosis vs. follow-up (P less than .001). Patients with optimal response to TKI had significantly higher PTPRG expression during follow-up vs. diagnosis (P less than .0005); however, no difference was observed in patients with a failed response to TKI (P = .312).

Study details: This study assessed PTPRG expression in 21 patients with CML (chronic phase, n=18; accelerated phase, n=3) treated with imatinib (n=12) or nilotinib (n=9) and 7 healthy individuals.

Disclosures: This study was funded by the Qatar National Research Fund, and open access funding was enabled by the Qatar National Library. The authors declared no conflicts of interest.

Source: Ismail MA et al. Sci Rep. 2021 Apr 23. doi: 10.1038/s41598-021-86875-y.

Key clinical point: Protein tyrosine phosphatase receptor gamma (PTPRG), a tumor suppressor gene, could serve as a new biomarker to evaluate therapeutic response to tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML).

Major finding: In patients with CML, PTPRG expression was significantly lower at diagnosis vs. follow-up (P less than .001). Patients with optimal response to TKI had significantly higher PTPRG expression during follow-up vs. diagnosis (P less than .0005); however, no difference was observed in patients with a failed response to TKI (P = .312).

Study details: This study assessed PTPRG expression in 21 patients with CML (chronic phase, n=18; accelerated phase, n=3) treated with imatinib (n=12) or nilotinib (n=9) and 7 healthy individuals.

Disclosures: This study was funded by the Qatar National Research Fund, and open access funding was enabled by the Qatar National Library. The authors declared no conflicts of interest.

Source: Ismail MA et al. Sci Rep. 2021 Apr 23. doi: 10.1038/s41598-021-86875-y.

Key clinical point: High cancerous inhibitor of protein phosphatase 2A (CIP2A) levels at diagnosis predicts subsequent disease progression and treatment failure in patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib or dasatinib.

Major finding: High vs. low CIP2A levels were associated with poor progression-free survival (P = .04) and freedom from progression (P = .03). Patients with high vs. low CIP2A levels had a higher chance of treatment failure at 5 years (41% vs. 7.5%; P = .002) in both imatinib- (45% vs. 11%; P = .02) and dasatinib-treated (36% vs. 4%; P = .007) patients.

Study details: Data come from an analysis of 172 patients with newly diagnosed CML-CP enrolled in phase 3 SPIRIT2 trial who were randomly allocated to frontline imatinib (n=90) or dasatinib (n=82).

Disclosures: This study was funded by Bristol Myers Squibb (BMS). The lead author reported research support and/or honoraria from Novartis, BMS, and Pfizer. Other authors declared no conflicts of interest.

Source: Clark RE et al. Cancers (Basel). 2021 Apr 29. doi: 10.3390/cancers13092155.

Key clinical point: High cancerous inhibitor of protein phosphatase 2A (CIP2A) levels at diagnosis predicts subsequent disease progression and treatment failure in patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib or dasatinib.

Major finding: High vs. low CIP2A levels were associated with poor progression-free survival (P = .04) and freedom from progression (P = .03). Patients with high vs. low CIP2A levels had a higher chance of treatment failure at 5 years (41% vs. 7.5%; P = .002) in both imatinib- (45% vs. 11%; P = .02) and dasatinib-treated (36% vs. 4%; P = .007) patients.

Study details: Data come from an analysis of 172 patients with newly diagnosed CML-CP enrolled in phase 3 SPIRIT2 trial who were randomly allocated to frontline imatinib (n=90) or dasatinib (n=82).

Disclosures: This study was funded by Bristol Myers Squibb (BMS). The lead author reported research support and/or honoraria from Novartis, BMS, and Pfizer. Other authors declared no conflicts of interest.

Source: Clark RE et al. Cancers (Basel). 2021 Apr 29. doi: 10.3390/cancers13092155.

Key clinical point: High cancerous inhibitor of protein phosphatase 2A (CIP2A) levels at diagnosis predicts subsequent disease progression and treatment failure in patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib or dasatinib.

Major finding: High vs. low CIP2A levels were associated with poor progression-free survival (P = .04) and freedom from progression (P = .03). Patients with high vs. low CIP2A levels had a higher chance of treatment failure at 5 years (41% vs. 7.5%; P = .002) in both imatinib- (45% vs. 11%; P = .02) and dasatinib-treated (36% vs. 4%; P = .007) patients.

Study details: Data come from an analysis of 172 patients with newly diagnosed CML-CP enrolled in phase 3 SPIRIT2 trial who were randomly allocated to frontline imatinib (n=90) or dasatinib (n=82).

Disclosures: This study was funded by Bristol Myers Squibb (BMS). The lead author reported research support and/or honoraria from Novartis, BMS, and Pfizer. Other authors declared no conflicts of interest.

Source: Clark RE et al. Cancers (Basel). 2021 Apr 29. doi: 10.3390/cancers13092155.

Key clinical point: Patients with chronic-phase chronic myeloid leukemia (CML-CP) receiving a second-generation tyrosine kinase inhibitor (TKI) frontline and fulfilling eligibility criteria for European LeukemiaNet 2020 treatment-free remission (TFR) recommendations had the highest molecular recurrence-free survival (MRFS) after TKI discontinuation.

Major finding: MRFS at 2 and 5 years were 51.8% and 43.8%, respectively. MRFS was significantly higher in patients who fulfilled TFR recommendations vs. those who did not (P = .005). Molecular recurrence was highest in patients treated with frontline imatinib not fulfilling TFR recommendations and lowest in patients treated with a second-generation TKI and who fulfilled the eligibility criteria.

Study details: This retrospective study assessed TFR eligibility and outcomes in 398 patients with newly diagnosed CML-CP treated with either imatinib (73%) or a second- or third-generation TKI (27%) as frontline therapy.

Disclosures: No specific funding source was identified. Some investigators including the lead author reported ties with various pharmaceutical companies. The authors declared no conflicts of interest.

Source: Etienne G et al. Cancer Med. 2021 May 14. doi: 10.1002/cam4.3921.

Key clinical point: Patients with chronic-phase chronic myeloid leukemia (CML-CP) receiving a second-generation tyrosine kinase inhibitor (TKI) frontline and fulfilling eligibility criteria for European LeukemiaNet 2020 treatment-free remission (TFR) recommendations had the highest molecular recurrence-free survival (MRFS) after TKI discontinuation.

Major finding: MRFS at 2 and 5 years were 51.8% and 43.8%, respectively. MRFS was significantly higher in patients who fulfilled TFR recommendations vs. those who did not (P = .005). Molecular recurrence was highest in patients treated with frontline imatinib not fulfilling TFR recommendations and lowest in patients treated with a second-generation TKI and who fulfilled the eligibility criteria.

Study details: This retrospective study assessed TFR eligibility and outcomes in 398 patients with newly diagnosed CML-CP treated with either imatinib (73%) or a second- or third-generation TKI (27%) as frontline therapy.

Disclosures: No specific funding source was identified. Some investigators including the lead author reported ties with various pharmaceutical companies. The authors declared no conflicts of interest.

Source: Etienne G et al. Cancer Med. 2021 May 14. doi: 10.1002/cam4.3921.

Key clinical point: Patients with chronic-phase chronic myeloid leukemia (CML-CP) receiving a second-generation tyrosine kinase inhibitor (TKI) frontline and fulfilling eligibility criteria for European LeukemiaNet 2020 treatment-free remission (TFR) recommendations had the highest molecular recurrence-free survival (MRFS) after TKI discontinuation.

Major finding: MRFS at 2 and 5 years were 51.8% and 43.8%, respectively. MRFS was significantly higher in patients who fulfilled TFR recommendations vs. those who did not (P = .005). Molecular recurrence was highest in patients treated with frontline imatinib not fulfilling TFR recommendations and lowest in patients treated with a second-generation TKI and who fulfilled the eligibility criteria.

Study details: This retrospective study assessed TFR eligibility and outcomes in 398 patients with newly diagnosed CML-CP treated with either imatinib (73%) or a second- or third-generation TKI (27%) as frontline therapy.

Disclosures: No specific funding source was identified. Some investigators including the lead author reported ties with various pharmaceutical companies. The authors declared no conflicts of interest.

Source: Etienne G et al. Cancer Med. 2021 May 14. doi: 10.1002/cam4.3921.

Key clinical point: Cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF) improved tyrosine kinase inhibitor (TKI)-related fatigue in patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Patients receiving 18-week CBT-TTF vs. control reported improvements in physical (P = .023), mental (P = .015), and social activity (P = .001), along with enhanced cognitions including self-efficacy (P = .001), helplessness (P = .003), fatigue catastrophizing and focusing on symptoms (both P less than .001).

Study details: Findings are from secondary analysis of a trial including 36 adults with CML-CP treated with a TKI, who reported moderate to severe fatigue and were randomly allocated to receive either CBT-TTF (n=22) or waitlist control (n=14).

Disclosures: This study was funded by the National Cancer Institute. Some coinvestigators reported grants, consultancy, advisory, and speakers’ bureau memberships from various pharmaceutical companies.

Source: Hyland KA et al. Ann Behav Med. 2021 May 15. doi: 10.1093/abm/kaab035.

Key clinical point: Cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF) improved tyrosine kinase inhibitor (TKI)-related fatigue in patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Patients receiving 18-week CBT-TTF vs. control reported improvements in physical (P = .023), mental (P = .015), and social activity (P = .001), along with enhanced cognitions including self-efficacy (P = .001), helplessness (P = .003), fatigue catastrophizing and focusing on symptoms (both P less than .001).

Study details: Findings are from secondary analysis of a trial including 36 adults with CML-CP treated with a TKI, who reported moderate to severe fatigue and were randomly allocated to receive either CBT-TTF (n=22) or waitlist control (n=14).

Disclosures: This study was funded by the National Cancer Institute. Some coinvestigators reported grants, consultancy, advisory, and speakers’ bureau memberships from various pharmaceutical companies.

Source: Hyland KA et al. Ann Behav Med. 2021 May 15. doi: 10.1093/abm/kaab035.

Key clinical point: Cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF) improved tyrosine kinase inhibitor (TKI)-related fatigue in patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Patients receiving 18-week CBT-TTF vs. control reported improvements in physical (P = .023), mental (P = .015), and social activity (P = .001), along with enhanced cognitions including self-efficacy (P = .001), helplessness (P = .003), fatigue catastrophizing and focusing on symptoms (both P less than .001).

Study details: Findings are from secondary analysis of a trial including 36 adults with CML-CP treated with a TKI, who reported moderate to severe fatigue and were randomly allocated to receive either CBT-TTF (n=22) or waitlist control (n=14).

Disclosures: This study was funded by the National Cancer Institute. Some coinvestigators reported grants, consultancy, advisory, and speakers’ bureau memberships from various pharmaceutical companies.

Source: Hyland KA et al. Ann Behav Med. 2021 May 15. doi: 10.1093/abm/kaab035.

Key clinical point: Findings from routine clinical practice are in concordance with results from clinical trials and confirm the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) who were resistant or intolerant to previous tyrosine kinase inhibitors (TKIs) or had T315I mutation. No new safety signals were identified.

Major finding: During a median follow-up of 15 months, major molecular response was achieved in 58% of patients with CML. Estimated 3-year overall survival and progression-free survival were 85.3% and 81.6%, respectively. Treatment termination because of adverse events occurred in 8 patients with CML.

Study details: Findings are from a prospective observational study including 33 patients with CML and 17 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Patients were initiated on ponatinib following intolerance, relapse, or refractoriness to prior TKIs, disease progression, or T315I mutation.

Disclosures: This study was funded by Incyte Biosciences Benelux BV. Some investigators reported research funding, advisory board memberships, consultancy, honoraria, travel expenses, and membership of the board of directors for various pharmaceutical companies including Incyte Biosciences Benelux BV.

Source: Devos T et al. Ann Hematol. 2021 May 4. doi: 10.1007/s00277-021-04507-x.

Key clinical point: Findings from routine clinical practice are in concordance with results from clinical trials and confirm the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) who were resistant or intolerant to previous tyrosine kinase inhibitors (TKIs) or had T315I mutation. No new safety signals were identified.

Major finding: During a median follow-up of 15 months, major molecular response was achieved in 58% of patients with CML. Estimated 3-year overall survival and progression-free survival were 85.3% and 81.6%, respectively. Treatment termination because of adverse events occurred in 8 patients with CML.

Study details: Findings are from a prospective observational study including 33 patients with CML and 17 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Patients were initiated on ponatinib following intolerance, relapse, or refractoriness to prior TKIs, disease progression, or T315I mutation.

Disclosures: This study was funded by Incyte Biosciences Benelux BV. Some investigators reported research funding, advisory board memberships, consultancy, honoraria, travel expenses, and membership of the board of directors for various pharmaceutical companies including Incyte Biosciences Benelux BV.

Source: Devos T et al. Ann Hematol. 2021 May 4. doi: 10.1007/s00277-021-04507-x.

Key clinical point: Findings from routine clinical practice are in concordance with results from clinical trials and confirm the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) who were resistant or intolerant to previous tyrosine kinase inhibitors (TKIs) or had T315I mutation. No new safety signals were identified.

Major finding: During a median follow-up of 15 months, major molecular response was achieved in 58% of patients with CML. Estimated 3-year overall survival and progression-free survival were 85.3% and 81.6%, respectively. Treatment termination because of adverse events occurred in 8 patients with CML.

Study details: Findings are from a prospective observational study including 33 patients with CML and 17 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Patients were initiated on ponatinib following intolerance, relapse, or refractoriness to prior TKIs, disease progression, or T315I mutation.

Disclosures: This study was funded by Incyte Biosciences Benelux BV. Some investigators reported research funding, advisory board memberships, consultancy, honoraria, travel expenses, and membership of the board of directors for various pharmaceutical companies including Incyte Biosciences Benelux BV.

Source: Devos T et al. Ann Hematol. 2021 May 4. doi: 10.1007/s00277-021-04507-x.